Lymphoma-Myeloma Hematology Grand Rounds

---

RSS

Occurs monthly on the 4th Wednesday starting on 1/25/2023 at 8:00 AM
Wednesday, January 25, 2023, 8:00 AM - 9:00 AM, MD Anderson - Virtual


AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance (1.00 hours)

This activity is aimed at dissemination of information regarding the pathophysiology, treatment, and health outcomes for patients with hematologic malignancies.

1. Describe pivotal Phase II Studies leading to FDA approval.
2. Describe provocative Phase I Studies examining Car-T in DLBCL and Myeloma.
3. Examine novel immune therapy approaches in Lymphoma.
4. Describe mechanism of resistance in Multiple Myeloma.

If you are interested in attending this series, contact Lisa Foucheaux-Heider - Activity Coordinator - at [email protected]

 

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 

The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.

Mitigation of Relevant Financial Relationships

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Date	Empty Column	Title
		No activities are currently published for this month.
No upcoming dates have been setup.